Retatrutide vs Semaglutide — Triple Agonist vs Single Agonist Comparison
Semaglutide and Retatrutide sit at opposite ends of the GLP class. Semaglutide activates one receptor (GLP-1) and is FDA-approved with the longest safety record in the class. Retatrutide activates three (GLP-1, GIP, and glucagon) and is still investigational, but Phase 3 trials show it producing nearly twice the weight loss. Here's how they compare.
| Retatrutide | Semaglutide | |
|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon (triple agonist) | GLP-1 only (single agonist) |
| Brand Names | None yet — investigational | Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) |
| FDA Approval | Phase 3 trials; approval expected 2027–2028 | Diabetes: 2017. Obesity (Wegovy): 2021 |
| Average Weight Loss | ~28.7% at 12mg over 68 weeks (TRIUMPH-4) | ~14.9% at 2.4mg over 68 weeks (STEP 1) |
| Blood Sugar Control | Reduces HbA1c ~2.0% | Reduces HbA1c ~1–2% |
| Dosing | Once weekly injection. 2 → 4 → 6 → 9 → 12 mg | Once weekly injection (Ozempic/Wegovy) or daily oral (Rybelsus). 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg |
| GI Side Effects | Nausea, vomiting, diarrhea — common, dose-dependent | Same — most well-characterized in this comparison |
| Unique Side Effects | Dysesthesia (skin tingling/burning) ~21% at 12mg | None unique |
| Cardiovascular Data | TRIUMPH-3 CVOT pending (2027+) | SUSTAIN-6 and SELECT — proven CV risk reduction |
| Other Approved Indications | None | Cardiovascular risk reduction; chronic kidney disease in T2D |
| Availability | Research-grade only — clinical trials and research peptide vendors | Prescription only (insurance/cash) |
| Long-term Safety Data | <2 years | 8+ years |
| Key Trial | TRIUMPH program Phase 3 | STEP 1, SUSTAIN, SELECT |
Choose Retatrutide if:
Maximum weight loss is the priority and FDA approval / prescription access aren't required. Best for research settings exploring the cutting edge of the GLP class.
Choose Semaglutide if:
You want the most established FDA-approved option with years of safety data, proven cardiovascular benefit, and the broadest list of approved indications. Best for users who want a long track record.
Consider the bigger picture:
For the full picture of the GLP class evolution, see the Semaglutide vs Tirzepatide vs Retatrutide 3-way comparison.
Bottom Line
Retatrutide is the most powerful weight loss peptide in trials so far. Semaglutide has the most established safety record, the only proven cardiovascular benefit in the class (SELECT trial), and the most approved indications. Retatrutide's dysesthesia signal (~21% at 12mg) is the most notable side-effect difference between the two.
For educational and research purposes only. Not medical advice.
Have a question about Retatrutide vs Semaglutide — Triple Agonist vs Single Agonist Comparison? Send us an email →